
Smoking or oxygen machine issue may have caused deadly fire at Massachusetts assisted-living home
The state's deadliest blaze in more than four decades has highlighted the lack of regulations governing assisted-living facilities that often care for low-income or disabled residents.
The state fire marshal, Jon Davine, said the presence of medical oxygen contributed to the spread of the July 13 fire at Gabriel House in Fall River. The blaze left some residents of hanging out windows of the three-story building screaming for help.
The fire in the blue-collar city in southern Massachusetts remains under investigation but authorities believe it happened unintentionally, Davine said at a news conference Tuesday.
'Please, there's truly no safe way to smoke. But smoking is especially dangerous when home oxygen is in use,' he said.
Members of the local firefighter's union have said a lack of emergency personnel staffing in the city made responding to the blaze more difficult, and made the fire itself deadlier.
Earlier Tuesday, Massachusetts Gov. Maura Healey said the state was releasing $1.2 million for Fall River to hire more emergency response personnel. She also said additional funds will be expedited for the state's municipal public safety staffing program.
'We are here today to listen to make sure that we understand what this community needs now and moving forward in the wake of this tragedy,' Healey said.
Healey said last week that a state agency that ensures regulatory compliance at assisted-living residences will investigate all 273 such facilities in Massachusetts to make sure they are prepared to protect residents during emergencies. She said Tuesday that work has begun.
The district attorney's office identified the 10th victim as Halina Lawler, 70, on Monday. The victims of the fire ranged in age from 61 to 86.
A resident of Gabriel House filed a lawsuit Monday alleging the facility was not properly managed, staffed or maintained, that residency rules were not enforced 'and emergency response procedures were not put in place.'
Trapped in his room during the fire, Steven Oldrid was in an 'already compromised physical condition' when he suffered smoke inhalation and lost consciousness, according to the complaint filed in Bristol County Superior Court. As a result, Oldrid says he has increased mobility restrictions and has racked up medical bills for treatment.
George K. Regan Jr., a spokesperson for the facility owned by Dennis Etzkorn, did not immediately respond to an email seeking comment on the lawsuit. A phone message was also left with Oldrid's attorney.
Public injury law firm Morgan & Morgan also said last week it was hired to investigate the fire by the family of one of the residents killed at Gabriel House.
Morgan & Morgan Communications Manager Emily Walsh said the law firm had already begun looking into whether the facility was adequately staffed and provided proper training to staff, as well as any potential code violations and possible failures of fire safety equipment.
Etzkorn has said he is cooperating with investigations into the fire. Gabriel House issued a statement Monday emphasizing the importance of finding out 'exactly what caused this catastrophe, and if there were factors that made it worse.' The statement said the facility placed a premium on residents' safety.
'Maintaining compliance with all safety and building codes has always been our priority, and there were quarterly inspections of the fire suppression system – the latest as recently as five days prior to the fire,' said the facility's spokesperson.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) with a price target of $216.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported that net revenues in Q1 reached $13.343 billion, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. Global net revenues for the quarter for the Immunology portfolio rose to $6.264 billion, reflecting a growth of 16.6% on a reported basis or 18.1% on an operational basis. AbbVie Inc. (NYSE:ABBV) also experienced growth in global net revenues in the Neuroscience portfolio to $2.282 billion, reflecting a 16.1% increase on a reported basis or 17% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target
Johnson & Johnson (NYSE:JNJ) ranks among the . On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts adjusted operational revenue growth of roughly 3.5% instead of the 2.5% midpoint estimate that was previously projected. Pixabay/Public Domain Johnson & Johnson (NYSE:JNJ) also raised its outlook for full-year earnings per share from $10.50 to $10.70 to a range of $10.80 to $10.90. The company cited stronger top-line performance, currency effects, and a lower anticipated impact from tariffs for this improvement. From its initial estimate of $400 million, the healthcare company now projects a $200 million tariff impact in 2025. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.